Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020473 (
hyperlipidemia
)
15,891
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Chloroquine is a drug with over 60 years of safe clinical use in the treatment of malaria. The multiple mechanisms of chloroquine action have appeared to be useful in the therapy of many miscellaneous disorders well beyond its original antimalarial purposes. This paper is focused on the application of chloroquine for the treatment of malaria, porphyria cutanea tarda, rheumatoid arthritis, palindromic rheumatism and lupus. The possibility of the use of chloroquine in the therapy of other disorders such as diabetes mellitus, AIDS,
hyperlipidemia
, sarcoidosis,
hypercalcemia
, and melanoma is reviewed. Mechanisms of action of the drug as well as side effects on metabolism are discussed in view of recent discoveries.
...
PMID:[Chloroquine--miscellaneous properties of the antimalarial drug]. 1210 61
Patients with primary hyperparathyroidism (PHPT) have an increased cardiovascular morbidity and mortality. Elevated serum calcium and/or PTH may directly contribute to vascular tissue damage, but the role of classic factors for atherosclerosis has not fully been evaluated in this disease. The aim of our study was to dissect the potential effect of
hypercalcemia
and/or high PTH from that of major cardiovascular risk factors (i.e. diabetes mellitus,
hyperlipidemia
, hypertension, obesity, smoking habit) on the carotid artery structure of patients with PHPT. Twenty-six consecutive patients with PHPT [subdivided into two groups according to the absence (n = 10) or the presence (n = 16) of one or more risk factors] and 15 normocalcemic healthy subjects as controls were studied. At ultrasonography, a significant increase (P < 0.001) of carotid mean and maximum intima-media thickness, as well as a significant reduction of lumen diameter (P < 0.05) were found in the PHPT group with risk factors, compared with the other two groups. This suggests that
hypercalcemia
and/or PTH elevation per se are not determinant of carotid atherosclerosis in PHPT, and that increased cardiovascular mortality and morbility in this disease is attributable to the combined presence of classic cardiovascular risk factors.
...
PMID:Ultrasound evaluation of carotid artery in primary hyperparathyroidism. 1272 60
Six classes of vertebrate animals were injected with massive doses of estrogen for various periods of time necessary to produce a grossly recognizable response. Swelling of the liver, associated with
hypercalcemia
, hyperproteinemia, and
lipemia
, occurred in Teleostei, Amphibia, Reptilia, and Aves, but not in Elasmobranchii or Mammalia. Calcium that was added to the serum was bound as a calcium proteinate complex, synthesized in the liver, and liberated into the plasma. The concentration of calcium per gram was considerably higher than in other oviparous animals. Teleostei, Amphibia, and Reptilia, produced one new component, protein-X(1), having a sedimentation constant of approximately 17S, and many properties of a protein previously described in birds as X(2). Calcium-binding capacity of teleostean and amphibian serum proteins was estimated at 25 to 35 mg. per gm. of the mixed proteins of the serum; reptilian serum proteins bound 55 mg. per gm. Estrogen-treated birds clearly produced two, rather than one, new proteins, a phosphoprotein, X(1), having a rate of 8.5S, and X(2), a phospholipid-lipoglycoprotein, 17S. The calcium-binding capacity was approximately 50 mg. per gm. of the mixed proteins of the serums. Circumstantial evidence suggests that the plasma proteins of oviparity appeared simultaneously with the evolution of bone as a tissue and an ultimobranchial gland having parathyroid function.
...
PMID:The partition of calcium and protein in the blood of oviparous vertebrates during estrus. 1377 20
Patients with primary hyperparathyroidism (PHPT) have impaired vasodilation both dependent and independent of endothelium. The aims of our study were to measure three different biochemical markers of endothelial activation, i. e., plasma thrombomodulin, soluble(s) E-selectin, and von Willebrand factor, in PHPT patients before and one year after successful parathyroidectomy, and to distinguish the potential effect of
hypercalcemia
and/or high parathyroid hormone from that of major cardiovascular risk factors (diabetes mellitus,
hyperlipidemia
, hypertension, obesity, smoking habit) on endothelial function. Twenty consecutive patients with PHPT subdivided into two groups according to the absence (n = 8) or presence (n = 12) of one or more risk factors, and fifteen healthy normocalcemic subjects were studied. Baseline thrombomodulin levels were similar in the groups with and without risk factors, and in controls. In contrast, sE-selectin and von Willebrand factor were higher in PHPT patients with risk factors than in those without risk factors (p < 0.05 and p < 0.01, respectively) and controls (p < 0.01). Neither thrombomodulin nor sE-selectin changed after parathyroidectomy in either PHPT group. Plasma von Willebrand factor decreased (p < 0.01) in patients without risk factors, while persisting at high levels in patients with risk factors. In conclusion, in spite of a limitation due to the small number of patients, our study suggests that classic cardiovascular risk factors seem to be the main determinants for the high plasma levels of sE-selectin and vWF in PHPT. Together with unaltered thrombomodulin and sE-selectin levels, a plasma vWF decrease after parathyroidectomy might reflect a specific mechanism of its endothelial calcium- and/or PTH-stimulated secretion in some PHPT patients without risk factors. Whether a vWF reduction after parathyroidectomy may be used as a biochemical index for improved endothelial function in PHPT patients without risk factors has yet to be demonstrated in larger studies.
...
PMID:Biochemical markers of endothelial activation in primary hyperparathyroidism. 1652 14
To examine whether acute pancreatitis is associated with use of valproic acid. Through the population-based hospital discharge registries we identified all patients with an incident hospitalization of acute pancreatitis in the counties of North Jutland (data 1991 to 2003), Aarhus (data 1996 to 2003), and Viborg (data 1998 to 2003), Denmark. From the Danish Civil Registration System, we selected 10 sex-matched and age-matched population controls per case on the basis of risk set sampling. All prescriptions of valproic acid and other antiepileptic drugs within 90 days (present users) or 91 to 365 days (past users) before hospital admission with acute pancreatitis, or index date among controls, were collected from the prescription databases in the counties. We performed conditional logistic regression to estimate the relative risk of acute pancreatitis after exposure to valproic acid or other antiepileptic drugs, adjusting for gallstone diseases, alcohol-related diseases,
hyperlipidemia
, and
hypercalcemia
. We included 3083 cases of acute pancreatitis and 30,830 population controls. The adjusted odds ratio (OR) for acute pancreatitis in present users of valproic acid was 1.9 [95% confidence interval (CI), 1.1-3.3); for past users, the adjusted OR was 2.6 (95% CI, 0.8-8.7). For users of other antiepileptic drugs, the corresponding adjusted ORs were 1.6 (95% CI, 1.2-2.2) and 1.8 (95% CI, 1.1-3.0). Use of valproic acid is associated with an elevated relative risk estimate for acute pancreatitis, but it was not materially different from past use or use of other antiepileptic drugs. Therefore, our data challenge the hypothesis that valproic acid is an independent risk factor for acute pancreatitis.
...
PMID:Valproic acid and risk of acute pancreatitis: a population-based case-control study. 1664 26
Acute pancreatitis and chronic pancreatitis are complex inflammatory disorders of the pancreas with unpredictable severity, complications, and clinical courses. Growing evidence for genetic risk and modifying factors, plus strong evidence that only a minority of patients with these disorders are heavy alcohol drinkers, has revolutionized our concept of these diseases. Once considered a self-inflicted injury, pancreatitis is now recognized as a complex inflammatory condition like inflammatory bowel disease. Genetic linkage and candidate gene studies have identified six pancreas-targeting factors that are associated with changes in susceptibility to acute and/or chronic pancreatitis, including cationic trypsinogen (PRSS1), anionic trypsinogen (PRSS2), serine protease inhibitor Kazal 1 (SPINK1), cystic fibrosis transmembrane conductance regulator (CFTR), chymotrypsinogen C (CTRC) and calcium-sensing receptor (CASR). Patients with mutations in these genes are at increased risk of pancreatitis caused by a variety of stresses including
hyperlipidemia
and
hypercalcemia
. Multiple studies are reporting new polymorphisms, as well as complex gene x gene and gene x environmental interactions.
...
PMID:Genetic aspects of pancreatitis. 2005 46
Glycogen storage disease type I (GSD I) is an autosomal recessive disorder caused by defects in the glucose-6-phosphatase complex. Deficient activity in the glucose-6-phosphatase-a (G6Pase) catalytic unit characterizes GSD IA and defects in the glucose-6-phosphate transporter protein (G6PC) characterize GSD IB. The main clinical characteristics involve fasting hypoglycemia, hyperuricemia, hyperlactatemia, and
hyperlipidemia
.
Hypercalcemia
arose as an unknown problem in GSD I patients, especially in those with insufficient metabolic control. The aim of the present study was to obtain the prevalence of
hypercalcemia
and to draw attention to the metabolic complications of GSD I patients, including
hypercalcemia
in poor metabolic control.
Hypercalcemia
frequency and the affecting factors were studied cross-sectionally in 23 GSD I pediatric subjects. Clinical diagnosis of GSD I was confirmed in all patients either through documentation of deficient G6Pase enzyme activity levels on liver biopsy samples or through G6PC gene sequencing of DNA.
Hypercalcemia
was detected in 78.3% of patients with GSD I. Different from the previous report about
hypercalcemia
in a GSD IA patient who had R83H and 341delG mutations, we could not identify any genotype-phenotype correlation in our GSD I patients. Hyperlactatemia and hypertriglyceridemia correlated significantly with
hypercalcemia
. Furthermore, no differences in serum calcium concentrations could be demonstrated between patients with optimal metabolic control. We observed
hypercalcemia
in our series of GSD I patients during acute metabolic decompensation. Therefore, we speculate that
hypercalcemia
should be considered as one of the problems of GSD I patients during acute attacks. It may be related with prolonged lactic acidosis or may be a pseudohypercalcemia due to
hyperlipidemia
that can be seen in GSD I patients with poor metabolic control.
...
PMID:Hypercalcemia in glycogen storage disease type I patients of Turkish origin. 2239 40
The use of statins may have unnatural effects. A 54-year-old woman was admitted to the hospital with an incidental finding of
hypercalcemia
(10.8 mg/dL). There was no disease other than
hyperlipidemia
, and the patient had been on a course of atorvastatin calcium 10 mg for 1.5 years. A workup investigation to diagnose the cause of
hypercalcemia
was completed. The investigation did not reveal any pathological diseases that may have caused the
hypercalcemia
. The
hypercalcemia
resolved after atorvastatin-calcium was stopped, and the patient developed
hypercalcemia
shortly after the initiation of the atorvastatin calcium. Here, we report a clinical case of recurrent
hypercalcemia
possibly induced by atorvastatin calcium administration.
...
PMID:Can atorvastatin calcium cause asymptomatic hypercalcemia? 2549 Mar 3
Acute pancreatitis is most commonly attributed to gallstones, alcohol abuse, and metabolic disorders such as
hyperlipidemia
and
hypercalcemia
. Medications are an infrequent yet commonly overlooked etiology of pancreatitis. Although several drugs have been implicated, antidiabetic agents are a rare cause for drug-induced pancreatitis. Canagliflozin is a new drug in the class of SGLT-2 inhibitors used for the treatment of type 2 diabetes mellitus. Serious reported side effects include renal impairment, hyperkalemia, and hypotension. Pancreatitis as a result of canagliflozin, however, is exceedingly rare. Here we describe a case of a 33-year old female who presented with severe acute pancreatitis in the setting of recent initiation of canagliflozin. Given the timing of her presentation and after excluding all other possible etiologies, it was determined that canagliflozin was the likely source of her illness. This case highlights the importance of identifying drug-induced pancreatitis, especially in novel drugs, as it is commonly neglected in patients with multiple medical comorbidities and those taking numerous medications. Prompt identification of drug-induced pancreatitis can improve management as well as decrease morbidity and mortality in these individuals.
...
PMID:Canagliflozin-induced pancreatitis: a rare side effect of a new drug. 2617 Jun 77
Acute pancreatitis can be attributed to numerous potential causes, such as alcohol abuse, chololithiasis, infection, lesions, tumors,
hypercalcemia
,
hyperlipidemia
, and medications. Among psychotropic medications, the use of some atypical antipsychotics, such as clozapine, olanzapine, quetiapine and risperidone, has been implicated in the development of acute pancreatitis, although the underlying mechanism has not been clarified. We describe the case of a young man with no other major medical problems, alcohol abuse or predisposing factors, who developed acute necrotizing pancreatitis following olanzapine administration, possibly through severe elevation of serum triglycerides. A pharmacogenomic analysis revealed the presence of the 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled (HTR2C) -759C genotype which is related to increased risk for metabolic syndrome.
...
PMID:Acute Necrotizing Pancreatitis Following Olanzapine Treatment and 759C/T Polymorphism of HTR2C Gene: A Case Report. 2635 10
<< Previous
1
2
3
4
Next >>